Brief: Poxel Announces Completion Of Patient Enrollment For The Times 3 Trial

Poxel SA

28/08/2018 07:07

Aug 28 (Reuters) - POXEL SA  POXEL.PA :
    * POXEL ANNOUNCES COMPLETION OF PATIENT ENROLLMENT FOR THE
TIMES 3
TRIAL IN THE PHASE 3 REGISTRATION PROGRAM FOR IMEGLIMIN, AN
INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN
    * PHASE 3 TIMES DATA READOUT IS ON TRACK FOR 2019
    * JAPANESE NEW DRUG APPLICATION SUBMISSION FOR IMEGLIMIN
TARGETED
IN 2020

Source text for Eikon:  ID:nBw1qj2wpa 
Further company coverage:  POXEL.PA 

 (Gdynia Newsroom:)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))